Drug Trial Radar · NCT06834542
Clinical Study of GT201 in the Treatment of Advanced Gynecological Tumors
Last checked: Nov 19, 2026Latest source record: Apr 27, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Terminated
Enrollment
1
Actual
Start
Nov 1, 2022
Primary completion
Dec 30, 2025
Study completion Dec 30, 2025
Sponsor
- Lead sponsor
- Grit BiotechnologyIndustry
- Sponsor type
- Industry
- First posted
- Feb 19, 2025
Design
- Study type
- Interventional
- Phase
- Early phase 1
- Allocation
- Not applicable (single group)
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years, up to 70 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This study is an early exploration clinical study with one arm. The study consists of two stages, namely the dose escalation stage and the dose extension stage:
Conditions
- Adult Gynecological Tumors
Interventions
Autologous tumor infiltrating lymphocyte injection(GT201)Biological
GT201 treatment for advanced gynecological tumors (advanced cervical cancer)
Primary outcomes
What the sponsor says the trial is designed to measure.
- Objective Response RateTime frame: 3 years
- Incidence and severity of adcersed events per CTCAE 5.0Time frame: 3 years
- Progression-Free SurvivalTime frame: 3 years
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Shanghai Jiaotong University School of Medcine, Renji Hospital Ethica Committee
Shanghai, Shanghai Municipality, China
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.